Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Carcinoma, Hepatocellular 3Waldenstrom Macroglobulinemia 2Sezary Syndrome 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Mycosis Fungoides 2Melanoma 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Prolymphocytic 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2Carcinoma, Non-Small-Cell Lung 2Burkitt Lymphoma 2Breast Neoplasms 2Uveal Melanoma 1Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Thrombocythemia, Essential 1

Interventions

Specimen Handling 14Magnetic Resonance Spectroscopy 11Taxes 9Biopsy 9veliparib 7Paclitaxel 7Carboplatin 7pembrolizumab 3olaparib 3Cyclophosphamide 32,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3(2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone 3talazoparib 2eribulin 2entinostat 2cediranib 2Radiotherapy 2Radiation 2Platinum 2Nivolumab 2Irinotecan 2Immunoglobulin G 2Gemcitabine 2Doxorubicin 2Disulfides 2Cisplatin 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 21,2-diaminocyclohexaneplatinum II citrate 2tremelimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Triple Negative Breast Neoplasms × Pharmacogenomic Testing × Clear all
NCT01071564 2015-04-15

RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 1 Terminated
13 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡